NasdaqCM - Nasdaq Real Time Price USD

Coya Therapeutics, Inc. (COYA)

Compare

5.24

+0.08

(+1.55%)

At close: December 20 at 4:00:03 PM EST

5.24

0.00

(0.00%)

After hours: December 20 at 4:09:38 PM EST

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

HOUSTON, December 18, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with Frontotemporal Dementia (FTD). The study is being conducted by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital. Topli

Business Wire 2 days ago

COYA
+1.55%
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

HOUSTON, November 25, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Executive Chairman Howard Berman, Ph.D. will participate in the 7th Annual Evercore HealthCONx Conference being held on December 3 – 5, 2024 at the Loews Coral Gables Hotel in Coral Gables, FL.

Business Wire 25 days ago

COYA
+1.55%
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

HOUSTON, November 19, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan.

Business Wire last month

COYA
+1.55%
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

HOUSTON, November 06, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended September 30, 2024.

Business Wire last month

COYA
+1.55%
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

HOUSTON, November 01, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that, as previously disclosed, Arun Swaminathan, Ph.D., has been promoted to Chief Executive Officer, effective today, November 1, 2024. Dr. Swaminathan was instrumental in executing several significant commercial transactions in his career, including Coya’s licensing transaction

Business Wire last month

COYA
+1.55%
Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results

Coya Therapeutics, Inc. ( (COYA) ) has issued an update. Coya Therapeutics announced positive results from a Phase 2 trial of low-dose interleukin-2 (LD IL-2) in Alzheimer’s patients, showing safety and cognitive stabilization benefits with the q4wks regimen. The trial highlighted significant improvements in biomarkers and cognitive function, supporting Treg modulation strategies for neurodegenerative diseases. The findings bolster confidence in advancing LD IL-2 treatments and potential combina

TipRanks last month

COYA
+1.55%
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease. The data was shared at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24). The study met its primary and secondary endpoints, demonstrating that treatment with low-dose interleukin-2 is safe and well-tolerated in patients with Alzheimer’s. Also Read: EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Dis

Benzinga last month

COYA
+1.55%
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)

HOUSTON, October 29, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that results from the placebo-controlled Phase 2 clinical trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease were announced today at the 17th Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid, Spain. The study was led by Dr. Alireza Faridar an

Business Wire last month

COYA
+1.55%
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease

HOUSTON, October 28, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces it will conduct a conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease (AD). These clinical results wil

Business Wire last month

COYA
+1.55%
Coya Therapeutics Announces Closing of $10.0 Million Private Placement

HOUSTON, October 23, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells ("Tregs"), announced today the closing of the sale of an aggregate of 1,379,314 shares of its common stock in a private placement at a price of $7.25 per share. The majority of investors in the offering were existing institutional stockholders of the Company.

Business Wire last month

COYA
+1.55%
Coya Therapeutics Announces $10.0 Million Private Placement

HOUSTON, October 22, 2024--Coya Therapeutics, Inc. (Nasdaq:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells ("Tregs"), announced today that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 1,379,314 shares of its common stock in a private placement at a price of $7.25 per share. The offering is expected to close on or abou

Business Wire last month

COYA
+1.55%
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100

HOUSTON, October 08, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chairman and CEO Howard Berman, Ph.D. has been recognized as a PharmaVoice 100 winner in the category of Biotech Pathfinders. The annual list recognizes the most inspiring people in the life sciences industry and is a another recognition of Dr. Berman’s impact as Coya’s CEO as

Business Wire 2 months ago

COYA
+1.55%
Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference

HOUSTON, September 24, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that CEO Howard Berman, Ph.D. and Chief Business Officer and incoming Chief Executive Officer Arun Swaminathan, Ph.D, will participate in a fireside chat at the Chardan 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 2:00pm ET. The fireside chat will be mod

Business Wire 2 months ago

COYA
+1.55%
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease

HOUSTON, September 16, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the direct CNS anti-inflammatory effect of subcutaneously administered COYA 302 in a preclinical inflammatory associated mouse model of Parkinson’s Disease (PD).

Business Wire 3 months ago

COYA
+1.55%
Here's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 3 months ago

COYA
+1.55%
Coya Therapeutics to Present at Upcoming Healthcare Conferences

HOUSTON, September 03, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that CEO Howard Berman, Ph.D. will present at two upcoming healthcare conferences.

Business Wire 3 months ago

COYA
+1.55%
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024

HOUSTON, August 19, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced that Arun Swaminathan Ph.D. has been promoted to the role of Chief Executive Officer effective November 1, 2024. He will succeed Dr. Howard Berman who will continue to serve in the capacity of Executive Chair.

Business Wire 3 months ago

COYA
+1.55%
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results

HOUSTON, August 12, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended June 30, 2024.

Business Wire 4 months ago

COYA
+1.55%
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid

HOUSTON, August 02, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announces that data from the IIT, a double-blind, placebo-controlled, phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer's Disease, conducted at Houston Methodist Research Institute and supported by the Gates Foundation and the Alzheimer’s Association wi

Business Wire 4 months ago

COYA
+1.55%
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

HOUSTON, July 31, 2024--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the filing of intellectual property protection for the combination of COYA 301, or recombinant human low dose interleukin-2 (LD IL-2), and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs).

Business Wire 4 months ago

COYA
+1.55%

Performance Overview

Return	COYA	S&P 500
YTD	-29.28%	+24.34%
1-Year	-29.57%	+24.38%
3-Year	+10.32%	+28.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Coya Therapeutics, Inc. (COYA)

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease

Coya Therapeutics Announces Closing of $10.0 Million Private Placement

Coya Therapeutics Announces $10.0 Million Private Placement

Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100

Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference

Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease

Here's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

Coya Therapeutics to Present at Upcoming Healthcare Conferences

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results

Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid

Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Performance Overview